Pinned
Vinod BalachandranMD
797 posts
Vinod BalachandranMD
@TheVinodLab
Founding Director Olayan Center for Cancer Vaccines @MSKCancerCenter | Cancer Surgeon-Scientist | Pancreas cancer | Cancer immunology | 2x dad, 2x ironman
1. ENTER #mRNAvaccines for #pancreaticcancer! Long-term #PDAC survivor story PART3. "Do #PDACs REALLY have vaccine neoantigens (NAs)"? (aren’t they lowly mutated?) If each patient = own NAs, how do you vaccinate? Maybe mRNA? But how? @Nature nature.com/articles/s4158… 👇🏽 [1/32]- Today, in @Nature, we reveal PART 2 of our investigations on “What IS going on in long-term survivors of #PancreaticCancer (#PDAC)?” “Is it REALLY the immune system?” Well…more evidence here - > nature.com/articles/s4158… Thread below [1/30]
- Replying to @TheVinodLab2. MAJOR BARRIER for Cancer Vaccines = How DO you make anticancer T cells of HIGH - Magnitude - Longevity - Function Can you teach T cells to recognize “self” ➕ persist ➕ function… in #PDAC??
- Today we report in @nature - group 2 innate lymphoid cells (ILC2s) are previously unrecognized cells that activate immunity in #pancreatic cancer. nature.com/articles/s4158…
- 1. Tertiary Lymphoid Structures (TLSs) – on demand lymphoid aggregates that assemble in inflamed tissues/cancer to regulate immunity But how? What molecule triggers? What cells induce? TODAY in @Nature nature.com/articles/s4158… Long-term #PDAC survivor PART4 – TLSs 🧵1/25
- Replying to @TheVinodLab and @Nature
- Replying to @TheVinodLab3. In ’23, we found that though wisdom was #PDAC ≈ no mutation-derived neoantigens (NAs)… Long-term #PDAC survivors HAVE NAs! If NA = immunogenic 👉🏾 longer survival 🧵: x.com/TheVinodLab/st… This led to the 1st phI trial of adjuvant RNA #PDAC Vaccines👇🏽
Today, in @Nature, we reveal PART 2 of our investigations on “What IS going on in long-term survivors of #PancreaticCancer (#PDAC)?” “Is it REALLY the immune system?” Well…more evidence here - > nature.com/articles/s4158… Thread below [1/30] - Replying to @TheVinodLab4. Where we found #PDACs harbor - NAs - NAs targetable with RNA - RNA NA vaccines induce potent CD8 T cells in 8/16 pts (responders) - Responders have better outcome (at 1.5-yr follow-up) Results🧵:1. ENTER #mRNAvaccines for #pancreaticcancer! Long-term #PDAC survivor story PART3. "Do #PDACs REALLY have vaccine neoantigens (NAs)"? (aren’t they lowly mutated?) If each patient = own NAs, how do you vaccinate? Maybe mRNA? But how? @Nature nature.com/articles/s4158… 👇🏽 [1/32]
- Replying to @TheVinodLab6. First, A. Do responders still have better outcome? Left = 1.5 yr follow-up Right = 3.2 yr follow-up Yes! 👇🏽
- Replying to @TheVinodLab20. PROUD & GRATEFUL to work with an AMAZING TEAM! Congrats Zach Sethna @PabloGuasp – brilliant! @Martina_Milig @CharReiche – superb! @bengrbm @CompOncMSK – !!!! @MSKCancerCenter @EileenMOReilly @BioNTech_Group @genentech Ugur Sahin, Özlem Türeci, Ira Mellman + others
- Very honored (and surprised!) to receive this. So lucky to work everyday @MSKCancerCenter with exceptionally talented clinicians and scientists determined to crack #PancreaticCancer. Much progress is needed!Congratulations to Dr. @TheVinodLab for receiving the prestigious @FNIH_Org Trailblazer award for his innovative + impactful work in #pancreascancer! @MSKCancerCenter @OncoAlert
- Replying to @TheVinodLab5. But… A. Do patients have better outcomes at longer follow-up? And B. Do the T cells last? And do they still work? (requisite features for any vaccine) C. And where do they come from? Answers👇🏽
- Replying to @TheVinodLab16. TAKE HOME In #PDAC, RNA NA vaccines make CD8 T cells of - multiyear longevity - substantial magnitude - durable effector function whose presence - correlates with delayed recurrence at 3-yr follow-up
